NEW YORK – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has established a new monthly record – July 2020 – with respect to its E-Commerce sales. For the 5thconsecutive month (during July 2020), the Company has generated record results from its highest margin E-commerce business segment. During July 2020, monthly E-Commerce grew by 50%+ on a sequential Month to Month basis. Additionally, the Company is off to a strong start for the month of August 2020.
The Company is excited about the upcoming launch of its newest product offering: Rainbow Deluxe Sampler Pack (“Rainbow Pack” or “Pack”). The Rainbow Pack is available exclusively on the Company’s E-Commerce website – priced @ $99.99 per Pack.
The Company is now pre-selling its Rainbow Deluxe Sampler Pack on its E-Commerce Website. Each Rainbow Pack contains 1 Blister Pack of each of the 6 distinct Tauri-Gum flavors/versions
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum Flavor: Peach-Lemon). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com
Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives. The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.
The Company is headquartered in New York City and operates a regional office in Barcelona, Spain. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.